What happens when you take escitalopram with St. John's wort?
Escitalopram (Lexapro, Cipralex) is the S-enantiomer of citalopram and one of the most selective SSRIs available. It blocks the serotonin transporter without much affinity for norepinephrine, dopamine, histamine, or muscarinic receptors. St. John's wort (Hypericum perforatum) is a botanical antidepressant whose key constituents - hyperforin in particular - also inhibit serotonin reuptake and elevate central serotonin tone. When both are taken together, the additive serotonergic effect can push synaptic serotonin into the range where serotonin syndrome develops.
Serotonin syndrome combines altered mental status (agitation, confusion, hallucination), autonomic instability (tachycardia, hypertension, fever, sweating, diarrhea, dilated pupils), and neuromuscular hyperactivity (tremor, clonus, hyperreflexia, rigidity). Mild cases mimic flu or anxiety; severe cases include hyperthermia above 40 degrees C, seizures, rhabdomyolysis, and death. There is no specific antidote - management is supportive.
The interaction is not only pharmacodynamic. Escitalopram is metabolized primarily by CYP2C19 (and to a lesser degree CYP3A4 and CYP2D6). St. John's wort is a strong inducer of CYP2C19, CYP3A4, CYP2C9, and P-glycoprotein. Sustained St. John's wort use can therefore reduce escitalopram exposure, blunting its antidepressant effect. So a patient who adds St. John's wort to escitalopram may simultaneously face higher serotonin syndrome risk (pharmacodynamic) and worse depression control (pharmacokinetic).
Why is this important?
Escitalopram is one of the most commonly prescribed SSRIs because of its favorable tolerability and dosing simplicity. St. John's wort remains a popular over-the-counter botanical, particularly in Europe and increasingly in North America, and patients often perceive it as a gentle alternative or complement to prescription antidepressants. The result is that the combination is regularly seen in clinical practice even though the U.S. National Center for Complementary and Integrative Health (NCCIH) and FDA-required prescribing information for escitalopram both warn against it.
The CYP2C19 angle is also clinically meaningful. Patients with reduced CYP2C19 function (so-called intermediate or poor metabolizers) already have higher baseline escitalopram levels, which would in theory make them more vulnerable to serotonergic adverse effects. Conversely, ultrarapid CYP2C19 metabolizers may not get adequate escitalopram exposure, and St. John's wort induction would push them further into subtherapeutic range. Either way, the combination creates an unpredictable target.
A subtle but important point: St. John's wort induction takes about a week to develop and can persist for one to two weeks after stopping the supplement. This means dose adjustments around the time of starting or stopping St. John's wort are tricky, and a patient who quits abruptly may have a delayed rise in escitalopram levels.
What should you do?
If you take escitalopram, do not start St. John's wort. If you currently take both, contact your prescriber promptly. Do not stop escitalopram on your own - abrupt discontinuation can cause discontinuation syndrome, and the interaction risk persists for at least a week or two after stopping St. John's wort. Seek emergency care if you have tremor, sweating, fever, fast heart rate, severe agitation, twitching, or muscle stiffness. Bring the supplement bottle.
If you and your prescriber decide to discontinue escitalopram, taper it under their guidance and plan for a washout of at least one to two weeks before introducing any other serotonergic agent. Most psychiatrists would recommend exploring a different prescription antidepressant rather than swapping to St. John's wort, because the supplement's potency varies substantially between brands and its induction effects complicate any future medication choices.
Disclose every supplement, tea, and herbal product to your prescribing clinician and pharmacist. Read multi-ingredient supplement labels: St. John's wort is often hidden in "mood," "calm," or "emotional support" blends, or listed only by Latin name (Hypericum perforatum) or regional name (Johanniskraut, millepertuis, hierba de San Juan).
Which specific products are affected?
The warning covers all forms of escitalopram, including Lexapro, Cipralex, and authorized generics in tablet and oral solution form. On the supplement side, it applies to any Hypericum perforatum product - standardized extracts (often labeled 0.3% hypericin or 3-5% hyperforin), capsules, tablets, tinctures, teas, and combination products. Many over-the-counter sleep, mood, and "women's wellness" blends contain St. John's wort.
Other serotonergic agents that compound risk include other SSRIs and SNRIs, tramadol, triptans, fentanyl, MDMA, dextromethorphan, linezolid, MAO inhibitors, lithium, tryptophan, and 5-HTP. Patients on escitalopram should treat any new serotonergic exposure as worth discussing with their prescriber.
The bottom line
Escitalopram plus St. John's wort is a high-risk combination that can both cause serotonin syndrome and reduce the antidepressant's effectiveness through CYP enzyme induction. The combination is flagged by NCCIH and standard prescribing references and should be avoided. If you take escitalopram, do not add St. John's wort, and disclose every herbal product to your healthcare team.